Freenome is a biotechnology company on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases. By applying advanced machine learning techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective.
The company has raised $238 million from investors such as RA Capital, Polaris Partners, Perceptive Advisors, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society?s BrightEdge Ventures, Data Collective Venture Capital, and Verily Life Sciences (formerly Google Life Sciences).
Total Funding: $237.6M
Funding Stage: Series C
Business Stage: Growth
Market: B2B
Company Size: 101 to 250
Founded: 2014
Aug 2020
- Freenome Raises $270M in Series C Round for Registration Study of CRC Liquid Biopsy Test
Aug 2019
- ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
Jun 2018
- Christian Doppler Research Grant Awarded to Freenome and the Medical University
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Freenome
Senior Machine Learning Research Engineer
San Francisco, California
Machine Learning Scientist
San Francisco, California
Staff Software Engineer - Infrastructure
South San Francisco, CA
Staff Software Engineer, Backend
South San Francisco, CA
Software Engineer - Infrastructure
South San Francisco, CA
